What frontline treatment would you offer a patient with AITL who is not a candidate for an anthracycline due to baseline cardiomyopathy?
Answer from: Medical Oncologist at Community Practice
I would probably offer this patient CEOP. No data to back this up, however. Incorporation of etoposide in addition to CHOP confers a progression-free survival advantage in younger patients with PTCL, so it's reasonable to assume the etoposide would have activity.
Comments
Medical Oncologist at Florida Cancer Specialists What is the role of HDAC inhibitors when anthracyc...
Medical Oncologist at The Ohio State University Comprehensive Cancer Center / James Cancer Hospital and Solove Research Institute One could consider HDACi. It's probably less likel...
What is the role of HDAC inhibitors when anthracyc...
One could consider HDACi. It's probably less likel...